Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.
Saved in:
| Title: | Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. |
|---|---|
| Authors: | Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dudzinski SO; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Marqueen KE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cha EE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nasr LF; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rooney MK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ahmed S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nze C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fayad LE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Flowers CR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Jan 31; Vol. 16, pp. 1517348. Date of Electronic Publication: 2025 Jan 31 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1517348 |
